Femasys receives CE mark for FemBloc, first non-surgical permanent birth control, for European market

FEMASYS INC

CE mark certification for entire FemBloc System under EU MDR 2017/745; can now be marketed in European Economic Area (27 EU + 3 EFTA states).
Follows earlier March 13, 2025 delivery system approval; combined approval marks first global regulatory endorsement.
Company plans initial commercial launch in Spain via existing distribution partnerships; also seeking additional country approvals.
FemBloc is a non-surgical permanent birth control alternative; U.S. FDA IDE pivotal trial continues enrollment for U.S. approval.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.